Abstract:Potential conflict of interest: Nothing to report. To the Editor: We read with great interest the article by Bessho et al., who demonstrated that, among the 15 genes uniquely expressed in the liver of patients with biliary atresia (BA), IL8 and LAMC2 were sufficient to distinguish subjects with BA from patients with non‐BA controls, with an accuracy of 95%.1 They conclude that hepatic expression of these two genes may serve as a biomarker of disease. Whereas we appreciate the findings, we would like to address a few issues that may help further clarify or confirm the findings. First, only 14 patients were included as non‐BA controls; the causes of disease were unknown for 64.3% (n = 9) (Supporting Table 1 of Bessho et al.). Moreover, 21.4% (n = 3) of the non‐BA controls were misclassified by IL8 and LAMC2 as BA (Supporting Table 2 of Bessho et al.). It is conceivable that some non‐BA diseases share a similar genetic signature or phenotypic traits with BA, and exhibit similar hepatic expression profiles. Indeed, as previously demonstrated, the IL‐8 level is higher in the BA and non‐BA groups than in normal controls, and the increased IL‐8 level is associated with the lymphocytic count and the degree of fibrosis in BA.2 Also, it has been known that viral infection can promote IL‐8 expression in the liver, which is associated with chronic liver disease.5 Thus, subjects with virus infection in the non‐BA groups might have a similar level of hepatic IL‐8 expression, compared with those in the BA group. In the present study, whether the false positivity by IL8 and LAMC2 observed in three patients in the non‐BA group was associated with infections with viruses such as rotavirus, cytomegalovirus, etc. is unknown. Second, it has been reported that IL‐8 mRNA increases in the liver, particularly in the late stage of BA (e.g., the degree of fibrosis represented by aspartate aminotransferase‐to‐platelet ratio index) and advanced age, and is associated with persistent jaundice, portal hypertension, and/or an increased inflammation and fibrosis in the liver.3 Thus, it is recommended that the patients included in the study be divided into different groups according to the degree of fibrosis (e.g., aspartate aminotransferase‐to‐platelet ratio index) and age (e.g., ≤60, 61‐90, and > 90days). Therefore, it would be interesting if Bessho et al. were to reassess their data by taking viral infection, the degree of fibrosis, and age into account. Alternatively, a larger case‐controlled study incorporating the above‐mentioned points is required.

The association of immune-related genes and the potential role of IL10 with biliary atresia

Identification of Liver Immune Microenvironment-Related Hub Genes in Liver of Biliary Atresia

The Aberrant Expression of HLA-DR in Intrahepatic Bile Ducts in Patients with Biliary Atresia: an Immunohistochemistry and Immune Electron Microscopy Study.

Association of T-helper cell cytokine level with age in patients with biliary atresia: a preliminary study.

A novel model based on immune-related genes for differentiating biliary atresia from other cholestatic diseases

Immune Characteristics in Biliary Atresia Based on Immune Genes and Immune Cell Infiltration

Interleukin Gene Polymorphisms In Chinese Children With Biliary Atresia

Genome-Wide Association Study Identifies A Susceptibility Locus for Biliary Atresia on 10Q24.2

Biliary Atresia Subtypes Based on the Immune Cells and Genes Expressions by Unsupervised Clustering Imply the Underlying Pathogenesis

Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia

Single‐cell and spatial transcriptomics reveal the fibrosis‐related immune landscape of biliary atresia

Mechanism of biliary atresia caused by T follicular helper cells-induced immune injury

Identification of diagnostic biomarkers and potential therapeutic targets for biliary atresia via WGCNA and machine learning methods

Unsupervised Clustering Reveals Distinct Subtypes of Biliary Atresia Based on Immune Cell Types and Gene Expression

Altered T-Cell Receptor β-Chain and Lactate Dehydrogenase Are Associated With the Immune Pathogenesis of Biliary Atresia

ANKRD1 and SPP1 As Diagnostic Markers and Correlated with Immune Infiltration in Biliary Atresia

Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia

WITHDRAWN: Identification and Immunological Characterization of Cuproptosis-Related Molecular Clusters in Biliary Atresia

Hepatic Expression of Interleukin 8 in Diagnosing Biliary Atresia

Correlation of Interleukin-33/ST2 Receptor and Liver Fibrosis Progression in Biliary Atresia Patients.

Association Of Two Toll-Like Receptor 4 Single Nucleotide Polymorphisms With Biliary Atresia In Chinese Patients